Aptevo Therapeutics, a biotech company, is at the forefront of developing five bispecific antibodies designed for both blood and solid tumors. Currently, two of these antibodies are undergoing clinical trials, while the remaining three are in the preclinical stages. This innovative approach holds great promise in the field of therapeutics, offering potential new treatment options […]
Tag: antibodies
Immune Variation Impact on Influenza Evolution
In an era where the magnifying glass is firmly focused on viral outbreaks, groundbreaking research led by Caroline Kikawa from the University of Washington has peeled back another layer of the complex interplay between population immunity and the evolution of influenza strains. The study, a fascinating exploration of the role individual immune responses play in […]
Optimizing Antibody Formulation for Drug Development
In the realm of drug development, the last lap of the race – formulating antibodies – is a Herculean task, akin to threading a microscopic needle while riding a roller coaster. It’s a scientific juggling act requiring the ultimate precision, balance, and control. Christy Eatmon, a global subject matter connoisseur from Thermo Fisher Scientific, reveals […]
Optimizing Monoclonal Antibody Scaling
In the ever-evolving biotech landscape, the translation of monoclonal antibodies (mAb) from preclinical to clinical settings has emerged as a sophisticated scientific endeavor, hinging on the intricacies of pharmacokinetic target-mediated drug disposition (PK-TMDD) models. This process requires a keen understanding of allometric scaling principles and their underlying assumptions regarding TMDD parameters. The translation of mAb […]
Streamlining Antibody Production with Phage Display
In the rapidly advancing field of synthetic biology, the advent of phage display technology has revolutionized monoclonal antibody production, heralding a new era of antibody research and development. This breakthrough has streamlined the traditionally laborious process of isolating and amplifying genetic material from B cells, offering a faster and more efficient approach to therapeutic antibody […]
Enhancing Signal Detection in Mass Cytometry
In the realm of systems biology, illuminating the darker corners of cellular processes is a formidable challenge. Yet, Harvard University’s Xiaokang Lun is pushing the boundaries of what’s possible by harnessing the power of DNA in an innovative way. His breakthrough method, amplification by cyclic extension (ACE), holds the potential to revolutionize the field of […]
Vivodyne’s $40 Million Raise to Bypass Animal Models
In a seismic shift that could herald a new era in preclinical drug testing, Philadelphia-based biotech startup Vivodyne has secured $40 million in Series A funding. The funds are set to propel the development of its groundbreaking robotic, AI-enabled platform, which is designed to test drug candidates on lab-grown human tissues. This ambitious endeavor sidesteps […]
C5aR1 as Biomarker for Cutaneous Squamous Cell Carcinoma
The burgeoning field of immuno-oncology has been revolutionized by the promise of targeting the C5a-C5aR1 axis for advanced cutaneous squamous cell carcinoma (cSCC), according to a recent report published in the American Journal of Pathology. The study’s findings have electrified the biotech landscape, suggesting a novel therapeutic approach that could significantly alter the course of […]
TNF-α Transformation: Innovating Inflammation and Immunity
In the unfolding drama of biomedical revolution, a familiar protagonist is taking on new roles. Tumor Necrosis Factor Alpha (TNF-α), a storied cytokine with a history of pivotal roles in immunomodulatory therapy, is shifting the paradigm of its functionality in 2024. Historically targeted for autoimmune disorders, TNF-α is now demonstrating a surprising versatility, expanding its […]
FDA Limits COVID-19 Vaccines to High-Risk Groups
Title: A New Era in COVID-19 Vaccination Strategy: FDA Shifts Focus to High-Risk Groups In an epoch-making move, the U.S. Food and Drug Administration (FDA) has charted a new course for the deployment of COVID-19 vaccines. A recent article in the New England Journal of Medicine unveiled the FDA’s revised strategy, which no longer recommends […]
Innovative Tri-Specific Antibodies for Cancer Immunotherapy
Purple Biotech announces their novel CAPTN-3 tri-specific antibody platform at EACR 2025. The company focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, a humanized monoclonal antibody that blocks CEACAM1 to target multiple cancer indications. NT219, a dual inhibitor small molecule, demonstrated anti-tumor activity in a […]
Analysts’ Insights on BioNTech’s Future
BioNTech, a Germany-based biotech company, is at the forefront of developing cancer therapeutics and vaccines for infectious diseases, including COVID. With a diverse oncology pipeline that includes mRNA-based drugs, cell therapies, bispecific antibodies, and ADCs, BioNTech has established partnerships with major pharmaceutical companies like Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Its COVID vaccine, Comirnaty, […]
Advancing Neurological Disease Treatment with Brain Organoids
Brain organoids represent a cutting-edge tool in the realm of biotechnology and pharmaceuticals, particularly in the study and potential treatment of neurological diseases. ACROBiosystems, a leading enterprise in this field, is dedicated to providing innovative solutions to address challenges from initial discovery to clinical application. Their range of life science tools, including recombinant proteins, antibodies, […]
Aquaporin-4 Antibody Titers Influence Neuromyelitis Optica Relapse
1 In a pivotal and meticulously conducted study involving 171 patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD), researchers have illuminated a powerful new biomarker pathway that could dramatically reshape disease monitoring and therapeutic approaches. The investigation focused on fluctuations in Aquaporin-4 immunoglobulin G (AQP4-IgG) antibody titers — a known hallmark of NMOSD — and […]
